论文部分内容阅读
目的:系统评价结直肠癌血中C反应蛋白(C-reactive protein,CRP)对预后的影响.方法:在PubMed和Embase数据库中系统检索关于血中CRP和结直肠癌预后关系的文献,文献检索日期截止至2015-05.使用Stata12.0统计软件对数据进行Meta分析,以风险比(hazard risk,HR)及95%可信区间(95%confidence interval,95%CI)作为效应量.同时进行亚组和敏感性分析.结果:本研究共纳入21篇文献,包含4242例结直肠癌患者.我们的结果显示结直肠癌患者血中CRP水平与总生存率、肿瘤特异性生存率和无病生存率相关且具有统计学差异.总生存率:HR=1.89,95%CI:1.52-2.35(P<0.001);肿瘤特异性生存率:HR=2.08,95%CI:1.42-3.04(P<0.001);无病生存率:HR=1.44,95%CI:1.25-1.67(P<0.001).基于取样时间、样本量和研究区域的亚组分析也得到相似的结果.此外,敏感性分析证实了我们结果的稳定性、准确性和可靠性.结论:我们的研究结果表明血中CRP高水平与结直肠癌患者不良预后相关.因此,CRP可以作为结直肠癌患者预后的重要指标.
Objective: To systematically evaluate the effect of C-reactive protein (CRP) on the prognosis of colorectal cancer. Methods: A literature review of the relationship between CRP and colorectal cancer prognosis in PubMed and Embase databases. The deadline is until 2015-05. Metadata analysis is performed using Stata 12.0 statistical software. The risk ratio (HR) and 95% confidence interval (95% CI) are used as the effect amount. Simultaneously Subgroup and sensitivity analysis. Results: A total of 21 articles were included in the study, including 4242 patients with colorectal cancer. Our results show that CRP levels and overall survival, tumor-specific survival and disease-free blood in patients with colorectal cancer The survival rate was correlated and statistically significant. The overall survival rate was: HR=1.89, 95%CI:1.52-2.35 (P<0.001); tumor-specific survival rate: HR=2.08, 95%CI:1.42-3.04 (P< 0.001); disease-free survival rate: HR = 1.44, 95% CI: 1.25-1.67 (P < 0.001). Similar results were obtained based on subgroup analysis of sampling time, sample size and study area. In addition, sensitivity analysis confirmed The stability, accuracy and reliability of our results. Conclusion: Our results show that high levels of CRP in blood Poor prognosis in patients with colorectal cancer. Thus, CRP can be used as an important indicator of prognosis in patients with colorectal cancer.